An In Vitro Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of Francisella tularensis SCHU S4 and Identifies Nitric Oxide as a Predictor of Efficacy by Igor Golovliov et al.
ORIGINAL RESEARCH
published: 25 November 2016
doi: 10.3389/fcimb.2016.00152
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 November 2016 | Volume 6 | Article 152
Edited by:
Alfredo G. Torres,
University of Texas Medical Branch,
USA
Reviewed by:
Tonyia Eaves-Pyles,
University of Texas Medical Branch,
USA
Cornelia Blume,
University of Southampton, UK
*Correspondence:
Anders Sjöstedt
anders.sjostedt@umu.se
Received: 10 September 2016
Accepted: 01 November 2016
Published: 25 November 2016
Citation:
Golovliov I, Lindgren H, Eneslätt K,
Conlan W, Mosnier A, Henry T and
Sjöstedt A (2016) An In Vitro
Co-culture Mouse Model
Demonstrates Efficient
Vaccine-Mediated Control of
Francisella tularensis SCHU S4 and
Identifies Nitric Oxide as a Predictor of
Efficacy.
Front. Cell. Infect. Microbiol. 6:152.
doi: 10.3389/fcimb.2016.00152
An In Vitro Co-culture Mouse Model
Demonstrates Efficient
Vaccine-Mediated Control of
Francisella tularensis SCHU S4 and
Identifies Nitric Oxide as a Predictor
of Efficacy
Igor Golovliov 1, Helena Lindgren 1, Kjell Eneslätt 1, Wayne Conlan 2, Amandine Mosnier 3,
Thomas Henry 3 and Anders Sjöstedt 1*
1 Laboratory for Molecular Infection Medicine Sweden, Department of Clinical Microbiology, Clinical Bacteriology, and Umeå
University, Umeå, Sweden, 2National Research Council Canada, Institute for Biological Sciences, Ottawa, ON, Canada,
3Centre International de Recherche en Infectiologie, Institut national de la santé et de la recherche médicale, U1111, Lyon,
France
Francisella tularensis is a highly virulent intracellular bacterium and cell-mediated
immunity is critical for protection, but mechanisms of protection against highly virulent
variants, such as the prototypic strain F. tularensis strain SCHU S4, are poorly
understood. To this end, we established a co-culture system, based on splenocytes from
naïve, or immunized mice and in vitro infected bone marrow-derived macrophages that
allowed assessment of mechanisms controlling infection with F. tularensis. We utilized
the system to understand why the clpB gene deletion mutant, 1clpB, of SCHU S4
shows superior efficacy as a vaccine in the mouse model as compared to the existing
human vaccine, the live vaccine strain (LVS). Compared to naïve splenocytes,1clpB-, or
LVS-immune splenocytes conferred very significant control of a SCHU S4 infection
and the 1clpB-immune splenocytes were superior to the LVS-immune splenocytes.
Cultures with the 1clpB-immune splenocytes also contained higher levels of IFN-γ,
IL-17, and GM-CSF and nitric oxide, and T cells expressing combinations of IFN-γ,
TNF-α, and IL-17, than did cultures with LVS-immune splenocytes. There was strong
inverse correlation between bacterial replication and levels of nitrite, an end product of
nitric oxide, and essentially no control was observed when BMDM from iNOS−/− mice
were infected. Collectively, the co-culture model identified a critical role of nitric oxide for
protection against a highly virulent strain of F. tularensis.
Keywords: F. tularensis SCHU S4, in vitro co-culture model, mouse immune response, correlates of protection
INTRODUCTION
Francisella tularensis is a highly virulent facultative intracellular bacterium causing the severe
disease tularemia in many mammalian species (Sjöstedt, 2007). Two subspecies are common
human pathogens, subspecies tularensis (type A), which causes disease with high mortality if
untreated, and the less aggressive subspecies holarctica (type B), which despite its lower virulence
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may cause serious illness in humans. Tularemia is widespread
over the Northern hemisphere and a significant health problem,
in particular in certain parts of Scandinavia, in parts of Eastern
Europe, and in Turkey, but a rather uncommon disease in
most other parts of the world. The live vaccine strain (LVS)
is a human vaccine strain, which confers efficacious protection
against laboratory-acquired infection, as demonstrated by the
fact that the incidence of tularemia among the laboratory staff
decreased by 95% after its introduction (Burke, 1977). Despite
this success, studies on volunteers in the 1960s revealed that it
did not confer efficacious protection against aerosol infection
[reviewed by Conlan et al. (Conlan, 2011)]. Therefore, there is
a need for development of more efficacious Francisella vaccines
and previously, we analyzed if defined mutants of SCHU S4
(type A) could serve as such vaccine candidates and identified
that the 1clpB mutant conferred superior efficacy compared to
LVS, despite that the former was more attenuated (Kadzhaev
et al., 2009; Conlan et al., 2010; Ryden et al., 2012). It encodes
an AAA+ chaperone, although the exact function in F. tularensis
is still unknown.
Due to the essential role of CMI for host protection against
tularemia, a thorough understanding of its characteristics will
be necessary to identify how the infection is controlled. There
is accumulating evidence that the protective mechanisms are
effectuated via a complex interplay of multiple T cell subsets and
other immune mechanisms, and not a single specific immune
activity (Elkins et al., 2007; De Pascalis et al., 2008, 2012, 2014;
Cowley and Elkins, 2011; Eneslätt et al., 2011, 2012; Mahawar
et al., 2013; Griffin et al., 2015). Thus, the mechanisms cannot
be delineated using simple proliferation assays but will require
assays that closely mimic the in vivo situation. Therefore, new
models are needed to better understand protective mechanisms
and validate potential correlates of protective immunity. In this
regard, a functional in vitro splenocyte-bone marrow-derived
macrophage (BMDM) co-culture assay for measuring potential
correlates of protection for tularemia vaccines was developed and
substantial work has been performed with the aim to establish
correlates of protection against F. tularensis (Cowley and Elkins,
2003; Cowley et al., 2005; Collazo et al., 2009; Elkins et al.,
2011; De Pascalis et al., 2012, 2014; Mahawar et al., 2013; Griffin
et al., 2015). Pascalis et al. showed that the greater efficacy of
LVS vs. attenuated derivatives correlated with relative bactericidal
activity in the co-culture system (De Pascalis et al., 2012). The
relevance of such co-culture assays has to some extent been
validated by the demonstration that the identified immune
molecules play important roles in vivo (Kurtz et al., 2013; Melillo
et al., 2013, 2014). A limitation of the published work using the
splenocyte-BMDM co-culture model has been the extensive use
of the attenuated LVS strain and there are very few studies, which
have utilized fully virulent F. tularensis (Mahawar et al., 2013;
Griffin et al., 2015).
The absence of any demonstrable correlate(s) of protection is
an obstacle to the licensure of F. tularensis vaccines. Tularemia
is in most countries an unusual disease and even in endemic
areas, it appears with very irregular intervals (Sjöstedt, 2007).
Therefore, efficacy in a vaccinated population will not be possible
to evaluate. Moreover, although challenge studies of volunteers
were performed in the 1950s (Saslaw et al., 1961a,b), such studies,
in view of the severity of respiratory tularemia, are very unlikely
to be approved today. Therefore, a tularemia vaccine, as well
as other vaccines against unusual, aggressive diseases, need to
be evaluated according to the FDA Animal Rule (Snoy, 2010).
The regulation stipulates that efficacy testing can be performed
exclusively using animal models, provided that the mechanisms
of action of the vaccine are sufficiently well characterized to
permit extrapolation of efficacy to humans. Only one vaccine has
so far been approved according to the Animal Rule (US. Food
Drug Administration., 2015).
Efficacy of experimental tularemia vaccines has been
demonstrated using mouse, rat, rabbit, and non-human primate
models, but none of these have been approved by FDA.
Thus, models to test tularemia vaccine efficacy will require
further characterization before they can be approved, e.g., the
identification of correlates of immunity and protection. This
would also include models that would not necessitate lethal
animal challenges. Therefore, we wanted to investigate if a co-
culture assay based on infection of mouse bone marrow-derived
macrophages could be utilized to assess vaccine efficacy against
the highly virulent SCHU S4 strain. In view of the previously
described superior vaccine-mediated protection conferred by the
vaccine candidate1clpB compared to LVS (Kadzhaev et al., 2009;
Conlan et al., 2010; Ryden et al., 2012), we asked if this superior
trait also was reflected using the co-culture assay. Indeed, we
observed that 1clpB-immune splenocytes conferred superior
control of the SCHU S4 strain compared to LVS-immune
splenocytes and efficacy strongly correlated with levels of nitric
oxide.
MATERIALS AND METHODS
Bacterial Strains
F. tularensis LVS was originally obtained from the American
Type Culture Collection (ATCC 29684). F. tularensis strain
SCHU S4 (F. tularensis subsp. tularensis) was obtained from the
Francisella Strain Collection of the Swedish Defense Research
Agency, Umeå, Sweden. The generation in our laboratory of
the 1clpB strain by allelic replacement of the clpB gene, a
procedure that did not introduce any recombinant DNA in the
strain, has been described previously (Conlan et al., 2010). All
bacteriological work related to the SCHU S4 strain was carried
out in a biosafety level 3 facility certified by the Swedish Work
Environment Authority.
Animals
In the experiments, Balb/c or C57/BL6 mice obtained from
Charles River, Germany were used. When required, mice were
immunized with a dose of approximately 5 × 103 CFU of the
LVS or the 1clpB strain subcutaneously. The ensuing infection
resulted in no or very mild objective symptoms between days 4
and 6 of the infection. Ethical approval for all of the described
mouse experiments was obtained from the Ethical Committee
on Animal Research, Umeå, Sweden, A99-11, and A67-14 and
the University of Lyon, France (CECCAPP) under the protocol
number #ENS_2012_061.
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Generation of BMDM
Bone marrow was flushed from femurs of Balb/c or C57BL6/J
mice with Dulbecco’s Modified Eagle Medium (DMEM).
Typically, femurs from two mice were used in each experiment.
Cells were washed, a single-cell suspension was prepared by
gentle pipetting in complete DMEM [DMEM supplemented
with 10% of heat-inactivated fetal bovine serum, 0.2 of mM
L-glutamine, (Life Technologies), 1mM of HEPES buffer (Life
Technologies), and 50 µM of β-mercaptoethanol), and 10% of
L-929 conditioned medium. After counting, 5 × 106 BMDM
in 10ml of DMEM were added to a 10 cm Petri dish and
incubated at 37◦C and 5% CO2. After 3 days, 5ml of complete
DMEM containing L-929 conditionedmediumwere added. After
7 days of total incubation, medium was removed, 10ml of cold
PBS/10mM EDTA was added and the dishes were incubated
on ice for 30 min. The macrophages were carefully collected by
pipetting, centrifuged, resuspended in complete DMEM and 5
× 105 cells per well were added to 24-well plates and incubated
overnight at 37◦C and 5% CO2 and then used in the co-culture
assay. The number of viable BMDMwas determined after trypan
blue staining using Vi-CELL XR cell viability analyzer (Beckman
Coulter).
Splenocyte Preparation
Four to 5 weeks following immunization of Balb/c or C57/BL6
mice, spleens were aseptically removed from mice and cells
were released by gently squeezing the organs with an L-shaped
needle. Splenocytes from three mice were used for each group.
Splenocytes were prepared essentially as described (Bosio and
Elkins, 2001). A single-cell suspension was prepared, centrifuged
and erythrocytes were lysed with ammonium chloride. Cells were
washed by centrifugation with PBS + 2% FBS, and resuspended
finally in complete DMEM. The number of viable splenocytes
was determined after trypan blue staining using Vi-CELL XR cell
viability analyzer (Beckman Coulter). The splenocytes were then
used either in the co-culture assay or in the in vitro recall response
assay.
Infection of the BMDM in the Co-culture
Assay
Bacteria were grown overnight on Gc-agar plates, resuspended
in PBS, and added to the BMDM monolayer at an MOI
of 1:5 (bacteria:BMDM). After uptake for 2 h, medium was
removed and the macrophage monolayer was washed twice using
sterile PBS at RT. One ml of cDMEM containing 20 µg/ml
gentamicin was added to each well, plates were incubated for
an additional 45min and washed twice with PBS. Following
the last wash, each BMDM monolayer was overlaid with 1ml
of complete DMEM with 2.5 × 106 of congenic splenocytes,
giving a ratio BMDM:splenocytes of 1:5. Bacterial counts were
determined by lysis of the cells and plating of serial dilutions
(Golovliov et al., 2003). In indicated cultures, 1mM of NG-
monomethyl-L-arginine (NMMLA) was added simultaneously
with the splenocytes and maintained for the remainder of the
experiment.
Optimization of the in vitro
Splenocyte-BMDM Co-culture Model
The in vitro co-culture assay was previously established for the
LVS strain (Bosio and Elkins, 2001; Cowley and Elkins, 2003).
We now optimized the assay so it reproducibly could be used
for the SCHU S4 strain as well. This involved the optimization
of the ratio between T-cells with the antigen-presenting cells. It
was found that a minimum of 4 × 105 BMDM per well and 5-
fold more immune splenocytes, i.e., a ratio of 1:5, resulted in
the best control of both intracellular LVS and SCHU S4. When
the ratio was 1:1, the growth inhibition of LVS and SCHU S4
was on average 0.7 ± 0.1 and 1.3 ± 0.4 log10 CFU, respectively,
less than the growth inhibition using the ratio of 1:5. A ratio
of 1:10 led to results similar to those using the 1:5 ratio. Also,
the role of the bacterial MOI was investigated and bacterial
uptake was determined by lysis of the cultures after addition of
bacteria for 120min and it was determined that an MOI of 1:5
(bacteria/BMDM) resulted in optimal growth inhibition.
In vitro Recall Response and Lymphocyte
Proliferation Assay
Splenocytes were prepared from naïve mice or from mice
immunized with LVS or 1clpB as described above and seeded at
2 × 105 in 200 µL of complete DMEM supplemented with 50
µM of β-mercaptoethanol per well in 96-well plates. Splenocytes
were stimulated with a 1:1 mix of formalin-fixed LVS (ffLVS)
and formalin-fixed SCHU S4 (ffSCHUS4) antigen at a final
concentration of 0.5 bacteria/splenocyte or without antigen and
incubated in a humidified atmosphere with 5% CO2 at 37
◦C.
After 3 days the proliferative response of the splenocytes was
detected by measuring the [3H]-thymidine incorporation as
previously described (Ericsson et al., 1994) or analyzed by FACS
as described below.
Nitrite Measurement
The amount of NO−2 in the culture supernatants after 72 h
incubation was determined by use of the Griess reagent
(Giovannoni et al., 1997). One hundred microliter of the culture
supernatant was mixed with 100 µl each of the Griess reagents,
p-Aminobenzenesulfonamide (58 mM in 5% H3PO4), and 2,6,8-
Trihydroxypurine (3.9 mM) (Sigma). After 10min of incubation
at RT, the absorbance at 540 nm was recorded. The concentration
of NO−2 was determined by preparing a standard curve of sodium
nitrite. The lower limit of detection in the assay was 1.0 µM, i.e.,
below that concentration, medium spiked with nitrite showed an
absorbance indistinguishable from that of buffer alone.
Multiplex Cytokine Analysis
Cell culture supernatants, 50 µL/well, were collected from the
same cell cultures as used for assessment of intracellular bacterial
replication and stored frozen at −80◦C until analyzed using a
commercial 23-plex kit (catalog #M60009RDPD) or a custom-
made 9-plex kit according to themanufacturer’s instructions with
a Bio-Plex 200 system (BioRad Laboratories Inc, Hercules, CA,
USA). The 9-plex kit contained following cytokines: IL-2, IL-6,
IL-12p40, IL-17, IFN-γ, MIP-1β, GM-CSF, RANTES, and TNF-α.
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Flow Cytometry Analysis of Surface
Markers and Intracellular Cytokine Staining
Cells were collected after 72 h of incubation from either the
lymphocyte proliferation assay or from the co-culture assay.
Non-adherent cells were transferred to a new plate and 5
µg/mL of Brefeldin A was added. Four h later, plates were
centrifuged for 3min at 500× g and supernatants were removed.
After blocking of the Fc γ receptors with CD16/CD32 mouse
BD Fc block (clone 2.4G2, BD Biosciences), cells were labeled
with cell surface marker monoclonal antibodies (mAb) and
conjugated intracellular cytokine mAb as recommended by BD
Biosciences. The following mAb conjugates were used: CD3-
APCCy7 (clone 17A2, BD Biosciences), CD4-AF700 (clone
RM4-5, BD Biosciences), CD8-PerCPCy5.5 (clone 53-6.7, BD
Biosciences), IFNγ-PE-CF594 (clone XMG1.2, BD Biosciences),
TNF-α-Brilliant violet 421 (clone MP6-XT22, BioLegend),
IL17A-PE/Cy7 (clone TC11-18H10.1, BD Biosciences). Aqua
Viability Dye (Molecular Probes/Invitrogen) was added to
distinguish live and dead cells. Cells were acquired using an LSRII
flow cytometer (BD Biosciences) with FACSDiva software (BD
Biosciences). Results were analyzed using FlowJo software (Tree
Star).
Data Analysis and Statistical Methods
Two sample 2-tailed t-test, Mann-Whitney U or for paired data,
Wilcoxon’s signed rank test, were used to identify significant
differences (P < 0.05) between data sets. To analyze correlation
between data sets, Spearman’s rank correlation test was used. A
correlation with a coefficient (RS) above 0.4 was considered to
demonstrate significant correlation, and a coefficient above 0.7
was considered to indicate strong correlation. When multiple
experiments formed the basis for the analysis, the cumulative
data were presented as boxplots. In each boxplot, the line through
each box shows the median, with quartile one, and three as the
lower and upper limits of each box. The end of the vertical lines
indicates maximum and minimum values, respectively.
RESULTS
Splenocyte Recall Response
Splenocytes from mice immunized with LVS or 1clpB were
stimulated with formalin-killed F. tularensis antigen in vitro
to measure the recall response of the T-cells with regard to
proliferation and expression of cytokines. To accommodate for
the different backgrounds of the two strains, a mixture prepared
of equal amounts from LVS and SCHU S4 was analyzed to
assess the immune reactivity. Both LVS- and 1clpB-immune
Balb/c splenocytes responded with very prominent proliferative
responses to the antigen and the responses were stronger,
although not significantly stronger, of 1clpB- compared to
LVS-immune splenocytes (P = 0.16; Figure 1A). Intracellular
staining for IFN-γ and TNF-α showed that the percentages of
CD4+ and CD8+ T-cells expressing the respective cytokine were
significantly higher (P < 0.05) among1clpB- than LVS-immune
splenocytes (Figures 1B–E).
Overall, the results show that 1clpB-immune splenocytes
demonstrated more prominent recall responses in vitro to the F.
tularensis antigen than did LVS-immune splenocytes.
Growth Inhibition of F. tularensis LVS and
Cytokine Production Conferred by LVS- or
1clpB-Immune Splenocytes
The capacity of splenocytes from LVS- or 1clpB-immunized
mice to inhibit the intracellular growth of LVS in splenocyte-
BMDM co-cultures was assessed. Addition of either type of
immune splenocyte to the cultures significantly inhibited growth
of LVS better than did naïve splenocytes, the median growth
and the interquartile (IQ) one and three for all experiments
performed were 3.2 [2.4, 3.8] and 2.4 [1.7, 3.4] log10 CFU
for LVS-immune splenocytes and 1clpB-immune splenocytes,
respectively, vs. 5.2 [4.9, 5.6] log10 CFU for naïve splenocytes (P
< 0.001 for immune vs. naïve). The 1clpB-immune splenocytes
showed superior control compared to LVS-immune splenocytes,
P < 0.001 (Figure 2A). Not only growth inhibition was more
prominent in cultures with 1clpB-immune than LVS-immune
splenocytes, but also levels of IFN-γ, IL-17, and GM-CSF in the
culture supernatants were higher (P < 0.001; P < 0.05 and P <
0.001, respectively; Figures 2B–D).
In total, levels of 23 cytokines were analyzed in the
supernatants from the co-cultures and 17 of those were found
to be upregulated more than 2-fold in cultures with either of the
immune splenocytes vs. cultures with naïve splenocytes, whereas
MIP-1α was the sole cytokine being suppressed in cultures
with immune splenocytes (Table S1). It was further analyzed
how the cytokine levels of the supernatants correlated to the
degree of protection, i.e., growth inhibition. Also, the correlations
between the levels of the 23 cytokines and IFN-γ were analyzed.
Growth inhibition was highly correlated (P < 0.01) to IFN-
γ, GM-CSF, IL-10, IL-13, MIP-1α, and RANTES and among
these cytokines, GM-CSF, MIP-1α, and RANTES were highly
correlated (P < 0.01) to IFN-γ (Table 1). In addition, IFN-γ was
highly correlated (P < 0.01) to IL-17, IL-6, IL-12p40, eotaxin,
G-CSF, MCP-1, and MIP-1β (Table 1). From the 23 cytokines,
9 cytokines were chosen for use in subsequent analyses, since
they all discriminated between levels in cultures with LVS- vs.
1clpB-immunized splenocytes.
In summary, several of the cytokines, including IFN-γ,
strongly correlated to growth inhibition. Superior containment
of LVS bacteria was observed in cultures with 1clpB- vs. LVS-
immune cells. The cytokine profile in the cultures with immune
splenocytes reflected a Th1-type immune response.
Characterization of Immune Splenocytes
from the LVS-Infected Co-cultures
To better understand the enhanced ability of the1clpB-immune
splenocytes to control the replication of F. tularensis LVS,
the percentage of IFN-γ-, TNF-α-, and IL-17-producing T
cells were quantified by FACS analysis. IL-17 has in several
publications been found to correlate to protection against F.
tularensis (Lin et al., 2009; Mahawar et al., 2013). Analysis
was performed on non-adherent cells from the cultures after
72 h of incubation. There were higher percentages of CD4+
and CD8+ T cells expressing IFN-γ in cultures from the
immunized groups vs. the naïve group (P < 0.05) and among
the immunized groups, cultures with1clpB-immune splenocytes
expressed higher percentages (P < 0.05) of IFN-γ-positive cells
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FIGURE 1 | Recall responses of LVS- (light gray boxes) or 1clpB-immune (dark gray boxes) splenocytes analyzed with regard to lymphocyte
proliferative responses (A), CD4+ T cells expressing IFN-γ (B), CD8+ T-cell expressing IFN-γ (C), CD4+ T cells expressing TNF-α (D), and CD8+ T-cell expressing
TNF-α (E) Antigen ratio is expressed as number of killed bacteria/splenocyte. Results shown represent data from 3 experiments. Levels in cultures with naïve
splenocytes were consistently <1500 cpm and showed no differences with or without antigen. Asterisks indicate P < 0.05 according to Wilcoxon’s signed rank test
for the pair-wise comparisons between LVS- and 1clpB-immune data for each antigen ratio.
among both the CD4+ and CD8+ subsets (Figure 3). Levels
of cells expressing either IL-17 or TNF-α were similar between
the immunized groups and the naïve group. Some studies have
demonstrated that polyfunctional T cells demonstrate good
correlation with host protection (Darrah et al., 2007; Derrick
et al., 2011) and we identified such F. tularensis-specific T cells
as part of the human immune response (Eneslätt et al., 2012).
Also in the splenocyte-BMDM co-culture model, we observed
the presence of polyfunctional F. tularensis-specific T cells,
since in cultures with immune splenocytes, CD4+ and CD8+
T cells expressing IFN-γ and IL-17 or IFN-γ and TNF-α were
significantly increased compared to cultures with naïve cells (P
< 0.05). In all instances, the frequencies of the bifunctional T
cells were significantly higher in cultures with 1clpB-immune
compared to LVS-immune splenocytes (P < 0.05) (Figure 3).
Also, trifunctional CD4+ and CD8+ T cells were increased
in cultures with immune splenocytes (P < 0.05) and, again,
more frequent among1clpB-immune compared to LVS-immune
splenocytes (P < 0.05; Figure 3). Median fluorescence intensity
(MFI) of the immune splenocytes was analyzed for IFN-γ, IL-17,
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FIGURE 2 | Growth of F. tularensis LVS and cytokine accumulation in the co-culture assay. Growth of LVS in cultures with naïve (white boxes), LVS-immune
(light gray boxes) or 1clpB-immune (dark gray boxes) splenocytes was determined after 72 h (A) and the accumulated levels of IFN-γ (B), IL-17 (C), and GM-CSF (D)
in these cultures. Results shown represent data from 16 experiments in graph A and 11 experiments in graphs (B–D). Growth was calculated as the log10 CFU of
cultures at 72 h subtracted with the log10 CFU of cultures at 0 h [median and IQ one and three 2.3 (2.1, 3.2)]. In graphs (B–D), the values are expressed as log10
fold-regulation of the indicated cytokine in relation to the concentration in cultures with naïve splenocytes. *P < 0.05, ***P < 0.001 according to Wilcoxon’s signed
rank test. In graphs (B–D), the significances indicate the pair-wise comparisons between LVS- and 1clpB-immune data for each cytokine and in graph (A) for the
indicated pair-wise comparisons.
and TNF-α. Whereas, there were no significant differences for the
latter two cytokines, 1clpB-immune splenocytes demonstrated
significantly higher MFI of IFN-γ expression among the CD4+ T
cell populations than did LVS-immune splenocytes, median levels
were 2430 [1890, 7710] vs. 1210 [670, 3930] (P < 0.05).
Collectively, the data demonstrated that there were qualitative
and quantitative differences between 1clpB- and LVS-immune
splenocytes with regard to cytokine expression, since the
1clpB-immune population contained higher frequencies of
polyfunctional CD4+ and CD8+ T cells expressing IFN-γ in
combination with IL-17 and/or TNF-α and also higher MFI of
the IFN-γ-expressing CD4+ T cells.
Growth Inhibition of F. tularensis SCHU S4
and Cytokine Production Conferred by
LVS- or 1clpB-Immune Splenocytes
In agreement with our present findings, the splenocyte-BMDM
co-culture assay has previously been demonstrated to mediate
efficient control of LVS infection, but few studies have analyzed
the requirements for the control of virulent F. tularensis strains
(Mahawar et al., 2013; Griffin et al., 2015). Therefore, the same
protocol as previously described for the LVS infection was used,
but the highly virulent strain, SCHU S4, was instead used to infect
the cultures. As was demonstrated for the LVS infection, 1clpB-
immune splenocytes conferred superior control of SCHU S4
compared to LVS-immune splenocytes (P< 0.001; Figure 4A). In
fact, the LVS-immune cells did not restrict the growth of SCHU
S4 to the same extent as of LVS, median growth was 4.2 [3.1, 4.4]
vs. 3.2 [2.4, 3.8], respectively (P < 0.001; Figures 2A, 4A). In
contrast, 1clpB-immune Balb/c-derived splenocytes conferred
as efficient growth inhibition of SCHU S4 as of LVS, median
growth was 2.8 [1.9, 3.8] and 2.4 [1.7, 3.4] log10 CFU, respectively
(P > 0.05; Figures 2A, 4A). The cytokine profile of SCHU S4-
infected cultures resembled that of LVS-infected cultures, but
many of the cytokines were somewhat higher expressed in the
cultures with SCHU S4 (Table S1). Thus, SCHU S4-infected
cultures with1clpB-immune splenocytes contained higher levels
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of IFN-γ, GM-CSF, and IL-17 than the cultures with LVS-
immune splenocytes (P < 0.01 for IFN-γ and GM-CSF and P <
0.05 for IL-17: Figures 4B–D).
In summary, LVS-immune cells did not control SCHU S4 as
well as it controlled LVS, whereas 1clpB-immune cells showed
superior control and controlled both strains to a similar extent.
1clpB-immune cells induced higher levels of IFN-γ, IL-17, and
GM-CSF than did LVS-immune cells.
Nitric Oxide Production in
Splenocyte-BMDM Co-Cultures
Nitrite was measured in the supernatants of splenocyte-BMDM
co-cultures infected with LVS and it was observed that the
levels strongly correlated to growth inhibition (Spearman’s rank
correlation coefficient [rho] = 0.679, P < 0.01; Figure 5A).
Nitrite levels were also highly correlated (P < 0.01) to levels of
IFN-γ, GM-CSF, IL-6, IL-10, IL-12(p40), and RANTES (Table 1).
1clpB-immune Balb/c-derived splenocytes stimulated higher
nitrite production than did LVS-immune splenocytes, medians
were 21 µM [16, 26] vs. 16 µM [10, 23], respectively (P < 0.05;
Figure 6). Also when SCHU S4 was the infecting agent, nitrite
levels strongly correlated to growth inhibition (rho = 0.745, P
< 0.001; Figure 5B) and, again, cultures with 1clpB-immune
splenocytes displayed significantly higher levels of nitrite than did
cultures with LVS-immune splenocytes, medians were 15 [9, 23]
and 9 [5, 20] µM, respectively (P< 0.01; Figure 6).
In summary, these results demonstrate that 1clpB-immune
splenocytes showed superior capacity compared to LVS-immune
TABLE 1 | Correlations between growth inhibition, nitrite levels, IFN-γ
levels and levels of other cytokines.
Growth inhibitiona IFN-γb Nitritec
Growth inhibition 1.000 0.481** 0.679**
IFN-γ 0.481d** 1.000 0.525**
Nitrite 0.679** 0.525** 1.000
GM-CSF 0.356** 0.447** 0.435**
IL-10 0.499** −0.007 0.560**
MIP-1α 0.576** 0.727** 0.238
IL-13 0.672** 0.566** 0.440*
RANTES 0.380** 0.718** 0.643**
IL-17 0.145 0.697** 0.241
IL-6 0.281* 0.898** 0.416**
IL-12(p40) 0.252 0.607** 0.488**
Eotaxin 0.353* 0.441** 0.186
G-CSF 0.066 0.664** −0.244
MCP-1 0.228 0.713** −0.450*
MIP-1β 0.307* 0.495** 0.342*
a Growth inhibition of F. tularensis LVS in cultures with LVS-immune or 1clpB-immune
splenocytes vs. naïve splenocytes in the in vitro assay after 72 h.
b Levels of cytokines measured in the supernatants of the in vitro assay after 72 h.
c Levels of nitrite measured in the supernatants of the in vitro assay after 72 h.
d Spearman’s rank correlation coefficient between indicated combination.
*P < 0.05; **P < 0.01.
splenocytes to stimulate nitrite production in the splenocyte-
BMDM co-cultures and identify nitrite as a correlate of growth
inhibition of both LVS and the highly virulent strain SCHU S4.
Nitric Oxide-Dependent Growth Inhibition
Since nitrite levels correlated to the growth inhibition of F.
tularensis effectuated by the immune splenocytes, it was further
investigated if there was a direct correlation between the growth
inhibition of F. tularensis and NO by use of the competitive
inhibitor of iNOS, NMMLA. This treatment significantly reduced
the growth inhibition of LVS or SCHU S4 conferred by the
immune Balb/c-derived splenocytes (Figures 7A,B) and also
reduced the nitrite production to about 1 µM compared to levels
of at least 8.0µM in its absence (Figures 7C,D). Levels in cultures
with naïve splenocytes were consistently below 1 µM.
The role of NO was further investigated by use of BMDM
derived from iNOS−/− C57BL/6 mice. It should be noted that
also these mice, like Balb/c mice, generate robust immunity after
vaccination, since amajority survived an intradermal challenge of
1900 CFU and all of 5 mice survived 190 CFU after intradermal
immunization with 1clpB (Table 2), whereas the lethal dose for
naïve mice was one CFU. In contrast, all of LVS-immunized mice
succumbed to a challenge of 19 CFU within 22 days and maximal
survival was even shorter when the challenge dose was 190 or
1900 CFU (Table 2). Thus, as for Balb/c mice (Conlan et al.,
2010), immunization with 1clpB confers superior protection in
C57BL/6 mice.
Similar to the splenocytes derived from Balb/cJ mice,
C57BL/6-derived 1clpB-immune splenocytes controlled growth
of LVS and SCHU S4 better than did LVS-immune splenocytes, P
< 0.05 and P < 0.01, respectively (Figures 8A,B), and induced
higher nitrite production in the cultures, P < 0.01 and P
< 0.05 for LVS- and SCHU S4-infected cultures, respectively
FIGURE 3 | Percentage of CD4+ and CD8+ T-cells expressing IFN-γ,
IFN-γ, and TNF-α, or TNF-α and IL-17, or all three cytokines in cultures
with naïve (red circles), LVS-immune (blue circles) or 1clpB-immune
(black circles) splenocytes incubated with LVS-infected BMDM for
72h. The percentages are expressed in relation to the CD3+ population.
Results shown represent data from three experiments. * P < 0.05 according to
Wilcoxon’s signed rank test for the pair-wise comparisons between LVS- and
1clpB-immune data for each cytokine combination.
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FIGURE 4 | Growth of F. tularensis SCHU S4 and cytokine accumulation in the co-culture assay. Growth of SCHU S4 in cultures with naïve, LVS-immune or
1clpB-immune splenocytes was determined after 72 h (A) and the accumulated levels of IFN-γ (B), IL-17 (C), and GM-CSF (D) in these cultures. Results shown
represent data from nine experiments. Growth was calculated as the CFU (log10) of cultures at 72 h subtracted with the CFU (log10) of cultures at 0 h, 2.3 [2.1, 3.0]. In
graphs (B–D), the values are expressed as log10 fold-regulation of the indicated cytokine in relation to the concentration in cultures with naïve splenocytes. * P < 0.05,
** P < 0.01, *** P < 0.001 according to Wilcoxon’s signed rank test. In graphs (B–D), the significances indicate the pair-wise comparisons between LVS- and
1clpB-immune data for each cytokine and in graph (A) for the indicated pair-wise comparisons.
(Figures 8C,D). Also in cultures with C57BL/6 cells, as in
cultures with Balb/cJ cells, the nitrite levels were highly correlated
to the growth inhibition of both LVS and SCHU S4 (rho =
0.745 and 0.771, respectively, P < 0.01). Further corroborating
the role of NO, the growth inhibition elicited by the immune
splenocytes was significantly lower (P < 0.001) in cultures with
iNOS−/− BMDM compared to C57BL/6 BMDM, whether or not
the cultures were infected with LVS or SCHU S4 (Figures 8A,B).
However, even in the absence of iNOS-derived NO, LVS-
and 1clpB-immune splenocytes still reduced the growth of
LVS, median net growth were 4.3 [3.9, 4.7] and 3.5 [3.4, 3.7]
log10 CFU, respectively, vs. 5.1 [4.7, 5.1] for naïve splenocytes;
1clpB-immune splenocytes being significantly superior to LVS-
immune splenocytes (P < 0.001; Figure 8A). In contrast, growth
inhibition of SCHU S4 in cultures with iNOS−/− BMDM was
very minor or non-existent for both LVS- and 1clpB-immune
splenocytes (Figure 8B).
Collectively, the data obtained with C57BL/6-derived cells
confirmed the results based on the Balb/c-derived cells, i.e.,
1clpB-immune splenocytes showed superior capacity compared
to LVS-immune splenocytes to control the F. tularensis infection
and the 1clpB-immune splenocytes induced higher levels
of nitrite production, which strongly correlated to growth
inhibition. In addition, iNOS was found to be critically
required for the growth inhibition of SCHU S4 and contributed
significantly to the control of LVS.
DISCUSSION
It is well-established that protection against many intracellular
pathogens is critically dependent on cell-mediated immunity,
however, there are no methods validated to identify correlates
of protection to these pathogens. In addition, for diseases like
tularemia, which is infrequent in most parts of the world, the
power of human clinical trials is unlikely to be sufficient to
provide unambiguous data regarding the efficacy of vaccine
candidates. To this end, the Animal Rule is an option for
licensing of future tularemia vaccines and this option is most
likely applicable to biodefense agents and sporadically occurring
diseases, both of which are relevant to tularemia. Critically
required in this regard is the identification of correlates of
protection, i.e., a measurement of a biologically relevant function
for and correlated to the degree of protection conferred in
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FIGURE 5 | Correlation of nitrite accumulation in cultures and growth
inhibition of LVS (A) or SCHU S4 (B) in the co-culture assay with LVS-
(circles) or 1clpB- (squares) immune splenocytes after 72 h of incubation.
Results shown represent data from 13 experiments for LVS-infected cultures
and five experiments for SCHU S4-infected cultures.
the animal model. For tularemia and other diseases caused
by intracellular pathogens, e.g., tuberculosis, much focus has
been on the role of IFN-γ as a correlate of protection.
Although important for the protection in vitro toMycobacterium
tuberculosis, levels of the cytokine have not shown good
correlation to protection in various clinical and experimental
models (Goldsack and Kirman, 2007; Mittrücker et al., 2007;
Jeevan et al., 2009). With regard to tularemia, IFN-γ appears to
be necessary, although not sufficient for protection (Elkins et al.,
2007; Conlan, 2011). Thus, there is a need to develop models to
better define the correlates of protection against tularemia.
The use of the splenocyte-BMDM co-culture model
demonstrates distinct advantages compared to commonly
used animal models for tularemia, since the number of animals
required will be far less and the mice that are immunized as
a source of splenocytes receive a sublethal dose that results in
few or no objective symptoms. Thus, the method leads to both
distinct reduction of the number of animals required, as well as
refinement, since the distress caused by the sublethal infection
FIGURE 6 | Nitrite levels accumulated after 72h in cultures with LVS- or
SCHU S4-infected BMDM co-cultured with naïve (white boxes),
LVS-immune (light gray boxes) or 1clpB-immune (dark gray boxes)
splenocytes. Results shown represent data from 13 experiments for
LVS-infected cultures and five experiments for SCHU S4-infected cultures. * P
< 0.05, ** P < 0.01 according to Wilcoxon’s signed rank test for the indicated
pair-wise comparisons.
will be minimal. In addition, the use of the co-culture model
allows for direct comparisons of correlates with those identified
in human models. In fact, a human co-culture model, based
on the use of adherent and non-adherent peripheral blood
mononuclear leukocytes from LVS-vaccinated individuals or
former tularemia patients, shows promise in this regard (Eneslätt
et al, unpublished). Since it is likely that human challenge studies
never will be performed in the future, the use of a human co-
culture model may be the only realistic way to identify correlates
of immunity and protection. A limitation of co-culture models
is there will be a selection of cell types included and the model
may therefore not be representative for certain organ-specific
immune responses in vivo. It should be noted that there are
examples when organ-specific F. tularensis co-culture models
have been utilized to overcome this limitation (De Pascalis et al.,
2014).
Although previous studies based on splenocyte-BMDM co-
culture models have revealed much about the vaccine-mediated
protection; both the prerequisites for protection against LVS as
well as putative correlates of protection, there have been very few
studies with virulent F. tularensis strains based on a co-culture
system (Mahawar et al., 2013; Griffin et al., 2015).
The present study used the LVS strain as benchmark for
F. tularensis vaccine efficacy. Vaccination with LVS effectively
prevents laboratory-acquired infection, but studies on volunteers
have revealed that it affords only marginal protection against
aerosol infection (Saslaw et al., 1961a,b; Burke, 1977). It was
hypothesized that it would be possible to generate a superior F.
tularensis vaccine and we and others have generated a number
of targeted mutants of SCHU S4 and their efficacy has been
evaluated using in vivo models with virulent F. tularensis strains
(Kadzhaev et al., 2009; Conlan et al., 2010; Shen et al., 2010;
Ryden et al., 2012; Santiago et al., 2015). In particular one
mutant, 1clpB, was found to confer superior efficacy to LVS, as
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FIGURE 7 | Growth of F. tularensis (A,B) and nitrite accumulation (C,D) in non-treated (light gray boxes) or NMMLA-treated (dark gray boxes) cultures. The data
shown is from three experiments. *** P < 0.001 according to Wilcoxon’s signed rank test for the pair-wise comparisons between non-treated or NMMLA-treated
cultures of each group.
TABLE 2 | Protective effect of LVS or 1clpB immunization of C57/BL6
mice against intradermal challenge with SCHU S4.
Immunizationa Challenge doseb Time of survival (days)
LVS 19 CFU 7, 8, 9, 11, 22
1clpB 19 CFU 24, >33, >33, >33, >33
LVS 190 CFU 7, 8, 12, 12
1clpB 190 CFU >33, >33, >33, >33, >33
LVS 1900 CFU 7, 8, 8, 9, 17
1clpB 1900 CFU 17, 22, 33, 33, 33
None 19 CFU 6, 6, 6, 6, 6
a Mice were intradermally immunized with 100,000 CFU of the LVS or the 1clpB strain.
b Mice were 6 weeks after immunization challenged intradermally with the indicated dose
of SCHU S4.
demonstrated by survival after infection with SCHU S4 (Conlan
et al., 2010). In agreement with the findings in both Balb/c and
C57BL/6 mice, our findings using the splenocyte-BMDM co-
culture method demonstrate that the1clpB-immune splenocytes
were superior to LVS-immune splenocytes in several aspects,
most notably that the 1clpB-immune splenocytes conferred
superior control of both LVS and SCHU S4 infection. In addition,
LVS-immune splenocytes conferred significantly less control of
SCHU S4 than LVS. Likewise, a previous study demonstrated
that LVS-immune splenocytes controlled SCHU S4 infection only
when pre-stimulated in vitro (Griffin et al., 2015).
Although previous studies based on various splenocyte-
BMDMco-culturemodels have revealedmuch about the vaccine-
mediated protection; both the prerequisites for protection against
LVS as well as putative correlates of protection, there have
been very few studies with virulent F. tularensis strains based
on a co-culture system (Mahawar et al., 2013; Griffin et al.,
2015) and, therefore, the present study provides important
information regarding the protective mechanisms operative
against the highly virulent SCHU S4 strain. In agreement with
the previous studies (Mahawar et al., 2013; Griffin et al., 2015),
our findings demonstrate a strong correlation between the ability
of the vaccine strains to confer protection to virulent strains
in vivo and their capability to efficiently prime the protective
efficacy of the immune cells as measured by the splenocyte-
BMDM co-culture model. In addition, our study reveals that the
quality of the immune responses elicited by LVS and 1clpB are
similar, although the response elicited by the 1clpB vaccine is
quantitatively more robust.
Multi-parameter flow cytometry has been used rather
extensively to characterize memory T cells and the technique has
enabled detailed descriptions of their phenotypic characteristics
and functional abilities. In various experimental models, it has
been argued that specific polyfunctional T cells demonstrate
good correlation with host protection. While promising in the
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FIGURE 8 | Growth of F. tularensis (A,B) and nitrite accumulation (C,D) in cultures with BMDM derived from C57BL/6 (light gray boxes) or iNOS−/− (dark gray
boxes) mice cocultured with naïve, LVS-immune or 1clpB-immune splenocytes after 72 h. (A) and (C) represent LVS-infected cultures and (B) and (D) SCHU
S4-infected cultures. Results shown in graphs A and B represent data from 6 experiments for iNOS−/− BMDM and 8 experiments for C57BL/6 BMDM and in graphs
C and D three experiments for iNOS−/− BMDM and five experiments for C57BL/6 BMDM. *** P < 0.001 according to Wilcoxon’s signed rank test for the pair-wise
comparisons between co-cultures with cells derived from C57BL/6 or iNOS−/− mice of each group.
context of mouse models of Leishmania and certain tuberculosis
vaccines (Darrah et al., 2007; Derrick et al., 2011), polyfunctional
T cells have in other cases failed to demonstrate correlation
to protection (Connor et al., 2010; Kagina et al., 2010; Harari
et al., 2011). Human responses to killed F. tularensis antigens
from the LVS or SCHU S4 strains have been characterized using
multi-parameter flow cytometry and it was found that IFN-γ
and MIP-1β strongly discriminated between immune and naïve
individuals (Eneslätt et al., 2012). Also in the present study,
we found evidence that the immune cell populations contained
polyfunctional T cells, expressing combinations of IFN-γ, TNF-
α, and IL-17. Interestingly, the relative frequencies of all variants
of polyfunctional CD4+ and CD8+ T cells expressing IFN-
γ was consistently higher among 1clpB- than LVS-immune
splenocytes.
Also in other important aspects, there were quantitative
differences between the immune responses triggered by the
1clpB- vs. the LVS-immune splenocytes, since the 1clpB-
immune splenocytes demonstrated stronger proliferative
responses and higher production of NO, IFN-γ, GM-CSF, and
IL-17, all of which correlated to growth inhibition. Altogether, all
of these properties of the 1clpB-immune splenocytes, together
with their superior ability to confer growth inhibition of SCHU
S4, help to explain the efficaciousness of 1clpB. An interesting
finding was that IFN-γ was the most strongly induced cytokine
after addition of immune splenocytes, whether or not they were
derived from 1clpB- or LVS-immunized mice. Considering
the critical role of IFN-γ for many aspects of immunity to
F. tularensis, the finding shows that the splenocyte-BMDM
co-culture system used herein mirrors relevant aspects of other
models of tularemia.
The effect of adding splenocytes derived from either C57BL/6
or Balb/cJ was also analyzed. In both instances, 1clpB-immune
splenocytes showed superior capacity compared to LVS-immune
splenocytes to control the F. tularensis infection and also to
induce production of higher levels of NO. This demonstrates
that the distinct differences between 1clpB-immune and LVS-
immune splenocytes were not affected by the genetic background
of the splenocytes.
It has been shown that control of LVS in a macrophage-
BMDM co-culture assay correlated with levels of nitrite (Bosio
and Elkins, 2001; Elkins et al., 2009). Our results using the co-
culture method provided strong evidence for the critical role
of NO for control also of the SCHU S4 infection as supported
both by experiments using an inhibitor of iNOS, as well as
iNOS-deficient BMDM. Although this may appear somewhat
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paradoxical, considering that NO plays a minor or insignificant
role in vitro (Lindgren et al., 2005; Edwards et al., 2010), it is likely
that NOproduction in the rather complex splenocyte-BMDMco-
culture model used herein confers additional effects compared
to the model based on monocytic cells only. In further support
of the important role of NO, it exerts a critical function in vivo,
since iNOS-deficient mice succumb even to the lowest inocula of
an LVS infection (Lindgren et al., 2004).
The enhanced NO production in 1clpB cultures was likely
dependent on the higher secretion of IFN-γ and IL-17, and
the higher frequency of polyfunctional T cells, expressing
combinations of IFN-, TNF-α, and IL-17, since these cytokines
regulate iNOS. Regulation of iNOS is in many aspects distinct
among species, but the critical roles of IFN-γ, TNF-α, IL-1β, and
IL-17 to induce its expression appears to be conserved regardless
of species (Pautz et al., 2010;Mühl et al., 2011).Many studies have
demonstrated a critical role of NO in various murine infectious
models, but there is also significant evidence supporting its role
for control of human infectious diseases. One notable example
is tuberculosis, the etiological agent of which is a facultative
intracellular bacterium, as for tularemia. It has been observed
that humanM. tuberculosis-infected monocytes produce NO and
this results in a bacteriostatic, and sometimes even bactericidal
effect (Landes et al., 2015). Further corroborating an important
role of NO, it has been observed that iNOS expression is
increased in human granulomas (Mattila et al., 2013). Malaria is
another important human disease where there is evidence for a
critical role of NO, since endogenous production of asymmetrical
dimethylarginine, an iNOS inhibitor, strongly correlated to
mortality (Yeo et al., 2010). Collectively, such findings suggest
that NO could have an important role in other human diseases,
such as tularemia, and, therefore, that the findings regarding the
superior protection conferred by1clpB in the mouse model also
will have relevance for the human situation.
Overall, our results provide new information as to why
1clpB is superior to LVS as a vaccine for protection against
highly virulent F. tularensis. The information is critical for
the understanding of protective mechanisms and thereby for
important for licensing of future vaccines against this potent
pathogen.
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